CAJ | 학술논문

目的探讨索拉非尼在临床治疗晚期原发性肝癌中的耐受性、安全性及相关疗效.方法对2008年11月至2009年11月间于我院诊断晚期原发性肝癌接受索拉非尼治疗的患者的相关临床数据进行分析,应用t检验及x2检验.结果本研究16例患者,平均生存时间12.37个月.治疗前Child评分A级者11例、B级3例、C级2例;治疗3个月后,治疗前A级患者中4例进展至B级,B级中2例进展至C级.治疗前MELD平均值为5.31,治疗后1个月为5.38(P＞0.05),治疗后3个月为6.67(P＞0.05).治疗前Child A级的患者平均总生存期为14.00个月,B/C级患者为8.80个月(P＞0.05).根据BCLC分期,B级患者的平均生存时间为13.70个月,C/D级患者的平均生存时间为10.17个月.结论索拉非尼治疗可延长晚期肝细胞性肝癌的总生存期,并且在不同肝功能状态的患者中均耐受性良好.
목적 탐토색랍비니재림상치료만기원발성간암중적내수성、안전성급상관료효.방법 대2008년11월지2009년11월간우아원진단만기원발성간암접수색랍비니치료적환자적상관림상수거진행분석,응용t검험급x2검험.결과 본연구16례환자,평균생존시간12.37개월.치료전Child평분A급자11례、B급3례、C급2례;치료3개월후,치료전A급환자중4례진전지B급,B급중2례진전지C급.치료전MELD평균치위5.31,치료후1개월위5.38(P＞0.05),치료후3개월위6.67(P＞0.05).치료전Child A급적환자평균총생존기위14.00개월,B/C급환자위8.80개월(P＞0.05).근거BCLC분기,B급환자적평균생존시간위13.70개월,C/D급환자적평균생존시간위10.17개월.결론 색랍비니치료가연장만기간세포성간암적총생존기,병차재불동간공능상태적환자중균내수성량호.
Objective To evaluate the tolerance, safety and curative effect of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods The clinical data of 16 cases of patients who had been diagnosed as unresectable HCC from November 2008 to November 2009 were retrospectively analyzed. Results The average survival time was 12.37 months. When stratified according to Child-Pugh score, there were 11,3 and 2 patients in grades A, B, C respectively before the therapy. One month later, one patient of grade A was transformed to B, and one of grade B to C. Three months later, 4patients of grade A was transformed to B, and 2 of grade B to C. The average model for end-stage liver disease ( M ELD) score before the therapy was 5.31, and that was 5.38 ( P ＞ 0. 05 ) one month later and 6.67(P ＞ 0.05 ) three months later. The average survival time of Child A and Child B/C was 14.00 and 8.80months respectively ( P ＞ 0.05). If stratified according to BCLC grade, the average survival time in grade B group and grade C/D group was 13.70 and 9.50 months respectively. Conclusion Sorafenib may prolong the total survival time of patients with advanced HCC, and it was well tolerated in patients with different states of liver function.